Kynurenic acid downregulates IL-17/1L-23 axis in vitro
- 420 Downloads
Exploring the function of interleukin (IL) 17 and related cytokine interactions have been proven useful toward understanding the role of inflammation in autoimmune diseases. Production of the inflammatory cytokine IL-23 by dendritic cells (DC’s) has been shown to promote IL-17 expression by Th17 cells. It is well established that Th17 cells play an important role in several autoimmune diseases including psoriasis and alopecia. Our recent investigations have suggested that Kynurenine-rich environment can shift a pro-inflammatory response to an anti-inflammatory response, as is the case in the presence of the enzyme Indoleamine 2,3 dioxygenase (IDO), the rate-limiting enzyme in tryptophan degradation and Kynurenine (Kyn) production. In this study, we sought to explore the potential role of kynurenic acid (KynA), in modulating the expression of IL-23 and IL-17 by DCs and CD4+ cells, respectively. The result of flow cytometry demonstrated that the frequency of IL-23-producing DCs is reduced with 100 µg/ml of KynA as compared with that of LPS-stimulated DCs. KynA (100 μg/ml) addition to activated T cells significantly decreased the level of IL-17 mRNA and frequency of IL-17+ T cells as compared to that of concanavalin (Con) A-activated T cells. To examine the mechanism of the suppressive role of KynA on IL-23/IL-17 in these cells, cells were treated with 3 μM G-protein-coupled receptor35 (GPCR35) inhibitor (CID), for 60 min. The result showed that the reduction of both adenylate cyclase (AC) and cyclic adenosine monophosphate (cAMP) by KynA is involved in suppression of LPS-induced IL-23p19 expression. Since GPCR35 is also detected on T cells; therefore, it is concluded that KynA plays an important role in modulating the expression of IL-23 and IL-17 in DCs and Th17 cells through inhibiting GPCR35 and downregulation of both AC and cAMP.
KeywordsKynA Kyn Dendritic cells IL-23 IL-17 Inflammation
This study has been supported by POP grant (CIHR PPP-133379). Sanam Salimi Elizei is supported by a WorkSafe BC Research Training Award. We would like to thank Dr. Ryan Hartwell for his kindness in editing the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors have no conflicts of interest to declare.
- 10.McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O’Shea JJ, Cua DJ (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10:314–324. doi: 10.1038/ni.1698 CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Doreau A, Belot A, Bastid J, Riche B, Trescol-Biemont M-C, Ranchin B, Fabien N, Cochat P, Pouteil-Noble C, Trolliet P, Durieu I, Tebib J, Kassai B, Ansieau S, Puisieux A, Eliaou J-F, Bonnefoy-Bérard N (2009) Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 10:778–785. doi: 10.1038/ni.1741 CrossRefPubMedGoogle Scholar
- 17.Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L (2008) Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 172:146–155. doi: 10.2353/ajpath.2008.070690 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Cosmi L, Maggi L, Santarlasci V, Capone M, Cardilicchia E, Frosali F, Querci V, Angeli R, Matucci A, Fambrini M, Liotta F, Parronchi P, Maggi E, Romagnani S, Annunziato F (2010) Identification of a novel subset of human circulating memory CD4+ T cells that produce both IL-17A and IL-4. J Allergy Clin Immunol 125(222–230):e4. doi: 10.1016/j.jaci.2009.10.012 Google Scholar
- 29.Nakajima K, Kanda T, Takaishi M, Shiga T, Miyoshi K, Nakajima H, Kamijima R, Tarutani M, Benson JM, Elloso MM, Gutshall LL, Naso MF, Iwakura Y, DiGiovanni J, Sano S (2011) Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 186:4481–4489. doi: 10.4049/jimmunol.1000148 CrossRefPubMedGoogle Scholar
- 32.Genovese MC, Van Den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62:929–939. doi: 10.1002/art.27334 CrossRefPubMedGoogle Scholar
- 34.Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL, Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191–1193. doi: 10.1126/science.281.5380.1191 CrossRefPubMedGoogle Scholar
- 39.Forouzandeh F, Jalili RB, Hartwell RV, Allan SE, Boyce S, Supp D, Ghahary A (2010) Local expression of indoleamine 2,3-dioxygenase suppresses T-cell-mediated rejection of an engineered bilayer skin substitute. Wound Repair Regen 18:614–623. doi: 10.1111/j.1524-475X.2010.00635.x CrossRefPubMedGoogle Scholar
- 47.Shi Q, Yin Z, Zhao B, Sun F, Yu H, Yin X, Zhang L, Wang S (2015) PGE2 elevates IL-23 production in human dendritic cells via a cAMP dependent pathway. Mediators Inflamm 2015:1–8Google Scholar
- 55.Cozzi A, Attucci S, Peruginelli F, Marinozzi M, Luneia R, Pellicciari R, Moroni F (1997) Type 2 metabotropic glutamate (mGlu) receptors tonically inhibit transmitter release in rat caudate nucleus: in vivo studies with (2S,1′S,2′S,3′R)-2-(2′-carboxy-3′-phenylcyclopropyl)glycine, a new potent and selective antagonist. Eur J Neurosci 9:1350–1355CrossRefPubMedGoogle Scholar
- 60.Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu B-M, Tato C, Yoshimura A, Hennighausen L, O’Shea JJ (2006) Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 103:8137–8142. doi: 10.1073/pnas.0600666103 CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Kaszaki J, Palásthy Z, Erczes D, Rácz A, Torday C, Varga G, Vécsei L, Boros M (2008) Kynurenic acid inhibits intestinal hypermotility and xanthine oxidase activity during experimental colon obstruction in dogs. Neurogastroenterol Motil 20:53–62. doi: 10.1111/j.1365-2982.2007.00989.x PubMedGoogle Scholar
- 62.Varga G, Erces D, Fazekas B, Fülöp M, Kovács T, Kaszaki J, Fülöp F, Vécsei L, Boros M (2010) N-Methyl-D-aspartate receptor antagonism decreases motility and inflammatory activation in the early phase of acute experimental colitis in the rat. Neurogastroenterol Motil 22(217–25):e68. doi: 10.1111/j.1365-2982.2009.01390.x Google Scholar
- 63.Tiszlavicz Z, Németh B, Fülöp F, Vécsei L, Tápai K, Ocsovszky I, Mándi Y (2011) Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. Naunyn Schmiedeberg’s Arch Pharmacol 383:447–455. doi: 10.1007/s00210-011-0605-2 CrossRefGoogle Scholar
- 69.Uh A, Simmons CF, Bresee C, Khoury N, Gombart AF, Nicholson RC, Kocak H, Equils O (2009) MyD88 and TRIF mediate the cyclic adenosine monophosphate (cAMP) induced corticotropin releasing hormone (CRH) expression in JEG3 choriocarcinoma cell line. Reprod Biol Endocrinol 7:74. doi: 10.1186/1477-7827-7-74 CrossRefPubMedPubMedCentralGoogle Scholar
- 70.Zhao P, Sharir H, Kapur A, Cowan A, Geller EB, Adler MW, Seltzman HH, Reggio PH, Heynen-Genel S, Sauer M, Chung TDY, Bai Y, Chen W, Caron MG, Barak LS, Abood ME (2010) Targeting of the orphan receptor GPR35 by pamoic acid: a potent activator of extracellular signal-regulated kinase and β-arrestin2 with antinociceptive activity. Mol Pharmacol 78:560–568. doi: 10.1124/mol.110.066746 CrossRefPubMedPubMedCentralGoogle Scholar